The reason for this is when we talk to patients who are seeking these treatments for obesity, whether it be ours or our competitors', a lot of people are having a hard time, said David Ricks, the chair and chief executive officer of Eli Lilly.
This is just an evolution of direct-to-consumer advertising, said Timothy Mackey, a professor at the University of California, San Diego, who studies the pharmaceutical industry.
[
add
]
[
|
|
...
]